Compound Screening TRIZ Cases

A diagnostic composition measures Orai1, TRPC3, and TRPC6 gene expression levels in biological samples to identify limb-girdle muscular dystrophy type 2H.

Nppb blocking agents target specific molecular pathways to manage chronic itch conditions without causing neurotoxicity.

A microfluidic device uses capillary elements to transfer samples from multiwell plates into channels for automated processing.

Protease-generated truncated chemokines modulate CCR1 and FPRL1 to treat inflammatory diseases.

Evaluates test substances by measuring mammalian FABP4 or FABP5 expression levels to identify agents suppressing glucose-dependent insulinotropic polypeptide elevation.

Antigen conjugation isolates target antibodies from serum samples, bypassing lengthy in vivo animal immunization processes.

Genome-wide siRNA screens identify malignancy signatures to target proteasome inhibitors against resistant basal-like breast tumors.

Mitochondria-targeted chaperone inhibitors accumulate in tumor cell mitochondria to induce selective cancer cell death.

New guinea pig cytomegalovirus strain CIDMTR resolves single-strain model limitations for congenital infection vaccine evaluation.

Heavy water probes resolve spatial resolution limits in noninvasive imaging by detecting deuterium incorporation into macromolecules via Raman spectroscopy.

Systematically varying electrophilic warheads balances reactivity and specificity to identify specific covalent inhibitors.

Identifies ETV6-NTRK3 fusion markers in digestive system cancers via segmented PCR amplification to enable precise inhibitor selection.

An antibody detects phosphorylation at serine 92 of HP1α to evaluate Aurora B kinase activity levels in cancer cells.

A co-culture system using cancer and stromal cells to assess anti-cancer drug effects in a three-dimensional structure.

Segmenting pathways into discrete components via universal arrays enables personalized therapy selection despite measurement complexity.

A flow cell apparatus with electrodes and imaging assemblies detects polynucleotide sequences to extract biological information.

BSEP-targeting fluorescent probes resolve preclinical reliability gaps by enabling precise detection of drug-induced cholestasis via optical signaling.

Lipids disassemble inert amyloid fibers into soluble oligomers, resolving complex purification bottlenecks to enable efficient compound screening.

Mass spectrometry profiles endogenous peptides from single-allele cells to train models, bypassing low-throughput biochemical affinity measurements.

Isolating IgSF CAM cytosolic tails reveals ligand-independent activation mechanisms, resolving the gap in understanding intracellular signaling pathways.

Compounds bind covalently to non-catalytic cysteine residues of IGF2 mRNA-binding proteins, inhibiting proliferative activity and reducing tumor growth.

A calcium biomaterial culture support system recreates the medullary environment for hematopoietic stem cell cultivation and drug testing.

A genetically encoded calcium indicator polypeptide detects transmembrane pore formation via fluorescent signals in cellular assays.

Beta-galactosidase fragment complementation distinguishes agonists and antagonists by translating ligand-receptor binding into measurable signals.

Isolated antibodies bind CD84 to downregulate anti-apoptotic activity in chronic lymphocytic leukemia cells.

Amantadine reduces lysosomal enzymatic activity while antiandrogenic agents decrease TMPRSS2 activity to block viral entry.

OPC-X assay screens for agents overcoming fibrinogen inhibition by assessing MBP+ cell presence and GFAP+ astrocyte suppression through BMP receptor blockade.

A 19-residue mini-protein scaffold uses a beta-strand loop and poly proline type II helix topology to achieve thermostability.

An intracellular antibody binds proliferating cell nuclear antigen without requiring cell permeabilization, enabling real-time cell cycle monitoring.

Lactic Acid Bacteria inhibit TRPV1 activation in the gut, avoiding cardiovascular complications from systemic antagonists.

A pharmaceutical composition inhibits cyclooxygenase and arachidonate-CoA ligase enzymes to eliminate senescent cells.

Covalent bridges stabilize MHC molecules, enabling efficient high-throughput TCR ligand screening.

FAMIN inhibitors reduce tumorigenesis by suppressing fatty acid metabolism immunity nexus activity in cancer patients.

A FRET-based assay uses genetically engineered cells to detect structural changes in actin-binding proteins upon compound exposure.

Peptides prevent αPKC binding to ALMS1 to enhance glucose absorption in adipocytes.

Fluorescent lipid translocation assays replace complex biochemical measurements to precisely screen TMEM16 scramblase modulators.

Soluble MD2 peptides intercept LPS to block integrin signaling, reducing harmful inflammation.

An intermediary polyacrylamide layer resolves the contradiction between high precision cell patterning and versatile pattern transfer capability.

SMARCA2 antagonists disrupt chromatin structure to treat cancers with decreased SMARCA4 function.

Computational design creates polypeptides binding hydrophobic transmembrane regions, overcoming antibody inaccessibility to enable specific protein modulation.

An anti-CD43 antibody binds a specific extracellular epitope to inhibit cancer stem cells.

AhR agonists compensate for microbiota ligand deficiency to reduce colitis severity and improve IBD treatment reliability.

In vitro muscle thin films enable high throughput measurement of contractile function in physiologically relevant tissue constructs.

ZYXY-M2 immortalized cell strain enables stable in vitro pathogenesis studies and high-throughput drug screening.

A probiotic strain selection method identifies effective strains by measuring neurotransmitter transporter expression profiles.